We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mesto imunoterapije pri zdravljenju raka.
- Authors
Grašič, Kuhar Cvetka
- Abstract
The immunotherapy era began in 1893. Nearly a hundred years later, the first immunotherapy drugs were approved, for instance interferon and interleukin. The role of the immune system in cancer is best represented by the cancer-immunity cycle. In the first step of the cycle, tumor neo-antigens are released and, subsequently, captured by the antigen-presenting cells. In the second step, neo-antigens are presented to the T-cells in the lymph nodes. But additional co-stimulatory signals are needed for the priming and the activation of T cells. At that level, the potential inhibitory signals inhibit or prevent the hyperactivation of T cells and autoimmunity. The activated T cells migrate through circulation into the tumor tissue. A tumor cell is detected by a T-cell receptor. The result of this process is the so-called T-cell killing. A tumor stroma, however, can present different inhibitory signals that inhibit the function of cytotoxic T cells. The article presents the different ways of influencing the cancer-immunity cycle and the readily-approved immunotherapy drugs.
- Publication
Onkologija, 2017, Vol 21, Issue 2, p6
- ISSN
1408-1741
- Publication type
Article